STONY BROOK, NY -- (Marketwired) -- 03/27/15

Applied DNA Sciences, Inc. (NASDAQ: APDN) (NASDAQ: APDNW) (Twitter: @APDN), a provider of DNA-based anti-counterfeiting technology, supply chain and product authentication solutions, announced that it has priced its previously announced underwritten public offering of 3,820,000 shares of its common stock and warrants to purchase up to an aggregate of 1,528,000shares of common stock, at a combined public offering price of $3.00. The warrants have an exercise price of $3.50 per share, expire on November 20, 2019 and will trade under the symbol APDNW.

The gross proceeds to the Company from this offering are estimated to be approximately $11.46 million before deducting the underwriting discount and other estimated offering expenses. The Company has granted the underwriters a 45-day option to purchase an aggregate of up to 573,000 additional shares of common stock and/or warrants to purchase up to 229,200 shares of common stock to cover over-allotments, if any. The offering is expected to close on or about April 1, 2015, subject to customary closing conditions.

The Company intends to use the net proceeds from this offering for general corporate purposes, including working capital, capital expenditures, business development and research and development and acquisitions of new technologies or businesses.

Maxim Group LLC is acting as the sole book runner for the offering with The Benchmark Company acting as Co-Manager.

The securities described above are being offered by Applied DNA Sciences pursuant to a "shelf" registration statement on Form S-3 (File No. 333-202432) filed with the Securities and Exchange Commission, or the SEC, which was declared effective by the SEC on March 10, 2015. Copies of the final prospectus supplement to be dated March 27, 2015 and accompanying base prospectus relating to the offering will be filed with the SEC and, when available, can be obtained by contacting Maxim Group LLC by telephone at 212-895-3475 or by e-mail at syndicate@maximgrp.com.

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Additional information can be found in the Company's filings with the SEC available at www.sec.gov and on the Company's website at www.adnas.com.

About Applied DNA Sciences

We make life real and safe by providing botanical-DNA based security and authentication solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion. SigNature® DNA describes the platform ingredient that is at the heart of all of our security and authentication solutions. SigNature DNA is at the core of a family of uncopyable products such as DNAnet®, our anti-theft product, SigNature® T, targeted toward textiles, and digitalDNA®, providing powerful track and trace. All provide a forensic chain of evidence and can be used to prosecute perpetrators.

Applied DNA Sciences common stock is listed on NASDAQ under the symbol APDN, and its warrants are listed under the symbol APDNW. 

Forward-Looking Statement

The statements made by APDN in this press release may be "forward-looking" in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe APDN's future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of APDN. Actual results could differ materially from those projected due to our short operating history, limited financial resources, limited market acceptance, market competition and various other factors detailed from time to time in APDN's SEC reports and filings, including our Annual Report on Form 10-K filed on December 15, 2014, as amended on March 6, 2015 and our subsequent quarterly report on Form 10-Q filed on February 9, 2015 which are available at www.sec.gov. APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.

investor contact:
Debbie Bailey
631-240-8817
debbie.bailey@adnas.com

media contact:
Enrique Briz
Dian Griesel Int'l.
212-825-3210
ebriz@dgicomm.com

web: www.adnas.com
twitter: @APDN